ArticleScience (New York, N.Y.)2017
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 242 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
242citing papers in PubMed, 2 pooled it
33.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
242 citing papers in PubMed, 2 syntheses or guidelines pooled it, 434 citations in OpenAlex.
- Association Between β-Adrenoreceptor Agonists and Antagonists and Parkinson's Disease: Systematic Review and Meta-Analysis.Pharmacoepidemiology and drug safety · 2025Pooled it
- Association between β2-Adrenoreceptor Medications and Risk of Parkinson's Disease: A Meta-Analysis.Medicina (Kaunas, Lithuania) · 2021Pooled it
- Cognitive Effects of Three β-Adrenoceptor Acting Drugs in Healthy Volunteers and Patients with Parkinson's Disease.Journal of Parkinson's disease · 2024Trial
- Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease.Nature aging · 2021Trial
- Clinical associations during the year before Parkinson's disease diagnosis in Taiwan: a nationwide claims-based case-control study.Annals of medicine · 2026Article
- Beta 2-adrenergic pathway combats Alzheimer's disease: Restoring cognition and synaptic integrity.Neural regeneration research · 2026Article
- Neuroinflammation and noradrenergic modulation with β2-adrenoceptors: Emerging therapeutic targets for Parkinson's diseases.Neural regeneration research · 2026Article
- Retrospective case-control study of pre-diagnosis observational and prescription data in Parkinson's disease.Scientific reports · 2026Observational
- Biased signaling of β2-adrenergic receptor in physiological and pathological states.Cellular & molecular biology letters · 2026Review
- Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.NPJ Parkinson's disease · 2026Article
- Sphingolipidoses: expanding the spectrum of α-synucleinopathies.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Therapeutic potential of propranolol in central nervous system disorders.Frontiers in psychiatry · 2026Review
- Neurosenescence, inflammaging and neuroinflammation in neurodegenerative disorders.Frontiers in aging · 2026Review
- Parkinson's disease incidence in glaucoma patients from israel: insights from a 20-year follow-up sample.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- The evolution of Alzheimer's target identification: Towards a fusion of artificial and cellular intelligence.The journal of prevention of Alzheimer's disease · 2025Article
- The clinical implication of β-arrestins-mediated signaling in memory and cognition.Molecular and cellular biochemistry · 2025Review
- Neuroprotection in Parkinson Disease.Neurology and therapy · 2025Review
- The Locus Coeruleus-Noradrenergic System in the Healthy and Diseased Brain: A Narrative Review.European journal of neurology · 2025Review
- Genetic Analysis of the X Chromosome Associates Loci with Progression of Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- The Search for Disease Modification in Parkinson's Disease-A Review of the Literature.Life (Basel, Switzerland) · 2025Review
182 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
24 authors at 9 institutions in 3 countries.
Shuchi MittalNeurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-4846-8898
Kjetil BjørnevikDepartment of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.ORCID 0000-0002-2892-6986
Doo Soon ImBrain and Mind Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada.ORCID 0000-0002-6477-9020
Adrian FlierlThe Parkinson's Institute and Clinical Center, Sunnyvale, CA 94085, USA.
Xianjun DongNeurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Joseph J LocascioNeurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-3439-1209
Kristine M AboNeurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-3626-705X
Elizabeth LongNeurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-3849-9241
Ming JinAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-5550-7533
Bing XuDepartment of Pharmacology, University of California at Davis, Davis, CA 95616, USA.
Yang K XiangDepartment of Pharmacology, University of California at Davis, Davis, CA 95616, USA.
Jean-Christophe RochetDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA.ORCID 0000-0002-6484-1541
Anders EngelandDepartment of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.ORCID 0000-0001-5620-9207
Patrizia RizzuGerman Center for Neurodegenerative Diseases (DZNE), Tübingen 72076, Germany.
Peter HeutinkGerman Center for Neurodegenerative Diseases (DZNE), Tübingen 72076, Germany.ORCID 0000-0001-5218-1737
Tim BartelsAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Dennis J SelkoeAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Barbara J CaldaroneDepartment of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Marcie A GlicksmanHarvard NeuroDiscovery Center, Harvard Medical School, Boston, MA 02115, USA.
Vikram KhuranaAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Birgitt SchüleThe Parkinson's Institute and Clinical Center, Sunnyvale, CA 94085, USA.
David S ParkBrain and Mind Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada.ORCID 0000-0002-4490-3784
Trond RiiseDepartment of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Clemens R ScherzerNeurogenomics Laboratory and Parkinson Personalized Medicine Program, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA. cscherzer@rics.bwh.harvard.edu.ORCID 0000-0002-0567-9193
Brigham and Women's Hospital · USGerman Center for Neurodegenerative Diseases · DEHaukeland University Hospital · NOMIND Research Institute · USParkinson's Institute and Clinical Center · USUniversity of California, Davis · USHarvard NeuroDiscovery Center · USNorwegian Institute of Public Health · NOPurdue University West Lafayette · US
Funding
Biomarkers for early intervention in Parkinson diseaseU01NS082157 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2012 to 2016
$2.5MParkinson Disease: Predicting the FutureU01NS095736 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2016 to 2018
$2.1MBiology of Native Alpha-Synuclein Tetramers in Parkinson's DiseaseR01NS083845 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SELKOE, DENNIS J · 2014 to 2018
$1.8MNINDS NIH HHS R01 NS083845NINDS NIH HHS U01 NS082157NINDS NIH HHS U01 NS095736
Abstract
Copy number mutations implicate excess production of α-synuclein as a possibly causative factor in Parkinson's disease (PD). Using an unbiased screen targeting endogenous gene expression, we discovered that the β2-adrenoreceptor (β2AR) is a regulator of the α-synuclein gene (
Indexed as
Gene Expression RegulationAcetylationAdrenergic beta-1 Receptor AgonistsAdrenergic beta-AntagonistsAlbuterolalpha-SynucleinAnimalsCell Line, TumorEnhancer Elements, GeneticHistonesHumansLigandsMiceNeuroprotective AgentsNorwayParkinson DiseaseAdrenergic beta-1 Receptor AgonistsAdrenergic beta-AntagonistsAlbuterolalpha-SynucleinHistonesLigandsNeuroprotective AgentsPropranololReceptors, Adrenergic, beta-2SNCA protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.